EPISODE · Sep 7, 2022 · 6 MIN
FDA D.I.S.C.O. Burst Edition: FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer and Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-mutant non-small cell lung cancer
from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Listen to a soundcast of the 8/10/2022 and 8/11/2022 FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer, and Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer.
Embed this episode
Ready to play
FDA D.I.S.C.O. Burst Edition: FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer and Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-mutant non-small cell lung cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.